Preliminary immunohistochemical characterization of a monoclonal antibody (pro:4-216) prepared from human prostate cancer nuclear matrix proteins

Partin, Alan W.; Briggman, Joseph V.; Subong, Eric N.P.; Szaro, Robert P.; Oreper, Ana; Wiesbrock, S M; Meyer, Jane L.; Coffey, Donald S.; Epstein, Jonathan I.

doi:10.1016/s0090-4295(97)00337-3

Cited by 27 publications

(17 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Following these findings, Partin et al [1997] later developed a monoclonal antibody PRO: 4-216 to detect what was reported to be the PC-1 protein. This monoclonal antibody was used to analyze frozen tissues from 20 cancerous, 22 BPH, and 22 normal regions from fresh human prostate specimens [Partin et al, 1997].…”

Section: Human Prostate Cancer-associated Nmpsmentioning

confidence: 99%

“…This monoclonal antibody was used to analyze frozen tissues from 20 cancerous, 22 BPH, and 22 normal regions from fresh human prostate specimens [Partin et al, 1997]. Immunohistochemical analysis showed that the PRO: 4-216 antibody was able to detect the presence of a unique protein in 85% (17 of 20) of the cancerous, 5% (1 of 22) of BPH, and 9% (2 of 22) of the normal prostate tissues.…”

Section: Human Prostate Cancer-associated Nmpsmentioning

confidence: 99%

See 1 more Smart Citation

Nuclear matrix proteins as biomarkers in prostate cancer

Leman

Getzenberg

2002

J of Cellular Biochemistry

View full text Add to dashboard Cite

The nuclear matrix (NM) is the structural framework of the nucleus that consists of the peripheral lamins and pore complexes, an internal ribonucleic protein network, and residual nucleoli. The NM contains proteins that contribute to the preservation of nuclear shape and its organization. These protein components better known as the NM proteins have been demonstrated to be tissue specific, and are altered in many cancers, including prostate cancer. Alterations in nuclear morphology are hallmarks of cancer and are believed to be associated with changes in NM protein composition. Prostate cancer is the most frequently diagnosed cancer in American men and many investigators have identified unique NM proteins that appear to be specific for this disease. These NM protein changes are associated with the development of prostate cancer, as well as in some cases being indicative of cancer stage. Identification of these NM proteins specific for prostate cancer provides an insight to understanding the molecular changes associated with this disease. This article reviews the role of NM proteins as tumor biomarkers in prostate cancer and the potential application of these proteins as therapeutic targets in the treatment of this disease.

show abstract

Section: Human Prostate Cancer-associated Nmpsmentioning

confidence: 99%

Section: Human Prostate Cancer-associated Nmpsmentioning

confidence: 99%

Nuclear matrix proteins as biomarkers in prostate cancer

Leman

Getzenberg

2002

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…These proteins are not expressed in detectable levels in tissue from patients with benign prostatic hyperplasia (BPH) or in normal tissue, but are found in prostate tumor tissue from the same patients [28]. PC-1, one such nuclear matrix protein, is currently being tested for use as a clinical marker [29].…”

Section: Genes and Chromosomesmentioning

confidence: 99%

The Dunning model

et al. 2000

View full text Add to dashboard Cite

“…There have been several NMPs isolated and characterized that are specific for individual cancers. For example, Partin and colleagues have identified both PC-1 and YL-1 as NMPs unique to prostate cancer (6,7). Additionally, we have developed a urine assay for the detection of bladder cancer based on BLCA-4, which is one of six unique bladder cancer NMPs identified in our laboratory (8).…”

Section: Introductionmentioning

confidence: 99%

Detection of Prostate Cancer with a Blood-Based Assay for Early Prostate Cancer Antigen

Paul¹,

Dhir²,

Landsittel

et al. 2005

Cancer Research

View full text Add to dashboard Cite

Prostate-specific antigen lacks specificity for prostate cancer, so the identification and characterization of a unique bloodbased marker for the disease would provide for a more accurate diagnosis, reducing both unnecessary biopsies and patient uncertainty. We previously identified a novel biomarker for prostate cancer, early prostate cancer antigen (EPCA). EPCA antibodies positively stained the negative biopsies of men who, as much as 5 years later, were diagnosed with prostate cancer. The goal of this study was to determine whether EPCA antibodies could be used in a clinically applicable plasma-based immunoassay to specifically detect prostate cancer. Using an EPCA-based ELISA, the protein was measured in the plasma of 46 individuals, including prostate cancer patients, healthy individuals, other cancer patients, spinal cord injury victims, and patients with prostatitis. With a predetermined cutoff value of 1.7 absorbance at 450 nm, only the prostate cancer population, as a whole, expressed plasma-EPCA levels above the cutoff. Statistical analysis showed a significant difference in EPCA levels between the prostate cancer population and each of the other groups, specifically the healthy donors (P < 0.0001), bladder cancer patients (P = 0.03), and spinal cord injury patients (P = 0.001). Sensitivity of the EPCA assay for prostate cancer patients was 92% whereas the overall specificity was 94%. Specificity for the healthy donors was 100%. Although larger trials are required, this initial study shows the potential of EPCA to serve as a highly specific blood-based marker for prostate cancer. EPCA, when coupled with prostate-specific antigen, may help reduce the number of both unnecessary biopsies and undetected prostate tumors. (Cancer Res 2005; 65(10): 4097-100)

show abstract

Preliminary immunohistochemical characterization of a monoclonal antibody (pro:4-216) prepared from human prostate cancer nuclear matrix proteins

Cited by 27 publications

References 16 publications

Nuclear matrix proteins as biomarkers in prostate cancer

Nuclear matrix proteins as biomarkers in prostate cancer

The Dunning model

Detection of Prostate Cancer with a Blood-Based Assay for Early Prostate Cancer Antigen

Contact Info

Product

Resources

About